CYTK vs SRRK
CYTK: A biopharmaceutical company pioneering small-molecule cardiac myosin inhibitors and muscle-directed therapies to improve heart and neuromuscular function in patients with debilitating diseases. SRRK: Scholar Rock develops myostatin-inhibiting monoclonal antibodies to treat rare neuromuscular diseases like spinal muscular atrophy, with lead candidate apitegromab anticipated for regulatory approval in 2026.
Side-by-side fundamentals
| Metric | CYTK | SRRK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $82.19 | $48.30 | |
| Market cap as of 2026-07-23 | $10.4B | $5.9B | |
| PEG as of 2026-07-23 | -0.41 | -0.40 | CYTK lower |
| Net margin as of 2026-07-23 | -784.0% | -237.0% | SRRK higher |
| Operating margin as of 2026-07-23 | -719.6% | -231.8% | SRRK higher |
| ROE as of 2026-07-23 | -131.2% | -162.9% | CYTK higher |
| ROA as of 2026-07-23 | -61.9% | -96.3% | CYTK higher |
| Debt / equity as of 2026-07-23 | 6.01 | 0.71 | SRRK lower |
| Revenue growth (YoY) as of 2026-07-23 | +450.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -2.4% | n/a | |
| Beta as of 2026-07-23 | 0.33 | 0.65 | |
| 1-year return as of 2026-07-22 close | +119.5% | +20.8% | CYTK higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.